NasdaqGS:NKTR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has Nektar Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NKTR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.7%

NKTR

-3.2%

US Pharmaceuticals

-2.4%

US Market


1 Year Return

-1.6%

NKTR

10.3%

US Pharmaceuticals

12.0%

US Market

Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned 10.3% over the past year.

Return vs Market: NKTR underperformed the US Market which returned 12% over the past year.


Shareholder returns

NKTRIndustryMarket
7 Day-12.7%-3.2%-2.4%
30 Day-8.1%-4.2%-6.5%
90 Day-20.1%4.1%8.4%
1 Year-1.6%-1.6%13.2%10.3%14.5%12.0%
3 Year-26.6%-26.6%23.8%14.7%34.8%25.8%
5 Year57.7%57.7%41.7%25.3%82.1%61.6%

Price Volatility Vs. Market

How volatile is Nektar Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nektar Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NKTR ($17.61) is trading below our estimate of fair value ($50.56)

Significantly Below Fair Value: NKTR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NKTR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: NKTR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NKTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NKTR is good value based on its PB Ratio (2.5x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Nektar Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

29.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NKTR's revenue (49.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: NKTR's revenue (49.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NKTR is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Nektar Therapeutics performed over the past 5 years?

-3.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NKTR is currently unprofitable.

Growing Profit Margin: NKTR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NKTR is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: NKTR has a negative Return on Equity (-34.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nektar Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NKTR's short term assets ($1.2B) exceed its short term liabilities ($124.0M).

Long Term Liabilities: NKTR's short term assets ($1.2B) exceed its long term liabilities ($214.7M).


Debt to Equity History and Analysis

Debt Level: NKTR is debt free.

Reducing Debt: NKTR has no debt compared to 5 years ago when its debt to equity ratio was 355.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NKTR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NKTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NKTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Howard Robin (67 yo)

13.67yrs

Tenure

US$9,939,250

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera ...


CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD9.94M) is above average for companies of similar size in the US market ($USD5.74M).

Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director13.67yrsUS$9.94m0.20%
$ 6.4m
Gilbert Labrucherie
Senior VP4.25yrsUS$7.49m0.065%
$ 2.0m
Jillian Thomsen
Senior VP of Finance & Chief Accounting Officer12.42yrsUS$1.92m0.096%
$ 3.0m
Jonathan Zalevsky
Chief Research & Development Officer0.92yrUS$7.27m0.17%
$ 5.2m
John Northcott
Senior VP & Chief Commercial Officer0.75yrUS$6.36mno data
Mark Wilson
Senior VP4.17yrsno data0.029%
$ 905.1k
Jennifer Ruddock
Senior Vice President of Strategy & Corporate Affairs1.67yrsno datano data
Mary Tagliaferri
Senior VP & Executive Clinical Fellow2.83yrsno datano data
Brian Kotzin
Senior VP of Clinical Development & Head of Immunology Program3.33yrsno datano data
Kevin Brodbeck
Senior Vice President of Manufacturing1.67yrsno datano data
Loui T. Madakamutil
VP and Head of Discovery & Research2.25yrsno datano data
Wei Lin
Senior Vice President & Head of Development1.83yrsno datano data

2.5yrs

Average Tenure

54yo

Average Age

Experienced Management: NKTR's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director13.67yrsUS$9.94m0.20%
$ 6.4m
Karin Eastham
Independent Director2yrsUS$352.73k0%
$ 0
Robert Chess
Independent Chairman of the Board21.42yrsUS$385.93k0.15%
$ 4.8m
R. Greer
Independent Director10.58yrsUS$379.23k0.095%
$ 3.0m
Roy Whitfield
Lead Independent Director1.67yrsUS$384.23k0.14%
$ 4.3m
Lutz Lingnau
Independent Director13.08yrsUS$361.23k0.011%
$ 355.7k
Jeffrey Ajer
Independent Director3yrsUS$351.48k0.0051%
$ 160.7k
Myriam Curet
Independent Director0.75yrUS$548.11k0%
$ 0

6.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: NKTR's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NKTR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

Nektar Therapeutics's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nektar Therapeutics
  • Ticker: NKTR
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.150b
  • Shares outstanding: 178.90m
  • Website: https://www.nektar.com

Number of Employees


Location

  • Nektar Therapeutics
  • 455 Mission Bay Boulevard South
  • San Francisco
  • California
  • 94158
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NKTRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1994
ITHDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1994
0UNLLSE (London Stock Exchange)YesCommon StockGBUSDMay 1994
NKTR *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 1994

Biography

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 06:11
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.